Mullard, A. FDA approves second microbiome-based C. difficile therapy. Nat. Rev. Drug Discov. 22, 436 (2023).

PubMed  Google Scholar 

Faecal Microbiota Transplant (FMT) (BiomeBank) (Therapeutic Goods Administration, 2022); https://www.tga.gov.au/resources/prescription-medicines-registrations/faecal-microbiota-transplant-fmt-biomebank

Fidler, B. Takeda ends deal with Finch as bumpy ride continues for microbiome drugs. BioPharma Dive https://www.biopharmadive.com/news/finch-takeda-end-ibd-microbiome-drug-deal/630592/ (2022).

AbbVie terminates deal on microbiome programs with Assembly Biosciences. S&P Global https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/abbvie-terminates-deal-on-microbiome-programs-with-assembly-biosciences-59106077 (2020).

AstraZeneca ends collaboration with Seres on microbiome-related cancer research. S&P Global https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/astrazeneca-ends-collaboration-with-seres-on-microbiome-related-cancer-research-61616703 (2020).

Wu, G. Flagship-backed microbiome biotech Evelo to shut down. BiopharmaDive https://www.biopharmadive.com/news/evelo-close-layoffs-shut-flagship-microbiome/700618/ (2023).

Vinluan, F. Microbiome biotech Kaleido Biosciences shutters amid cash crunch, drug setbacks. MedCity News https://medcitynews.com/2022/04/microbiome-biotech-kaleido-biosciences-shutters-amid-cash-crunch-drug-setbacks/ (2022).

Waldron, J. Bear market strikes again: 4D Pharma sinks into administration as creditor calls in loans. Fierce Biotech https://www.fiercebiotech.com/biotech/bear-market-strikes-again-4d-pharma-sinks-administration-creditor-calls-loans (2022).

Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492–506 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Ratsika, A., Cruz Pereira, J. S., Lynch, C. M. K., Clarke, G. & Cryan, J. F. Microbiota–immune–brain interactions: a lifespan perspective. Curr. Opin. Neurobiol. 78, 102652 (2023).

Article  CAS  PubMed  Google Scholar 

Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65(2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Almeida, A. et al. A new genomic blueprint of the human gut microbiota. Nature 568, 499–504 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sorbara, M. T. & Pamer, E. G. Microbiome-based therapeutics. Nat. Rev. Microbiol. 20, 365–380 (2022).

Article  CAS  PubMed  Google Scholar 

Merrick, B. et al. Regulation, risk and safety of faecal microbiota transplant. Infect. Prev. Pract. 2, 100069 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information (US Food and Drug Administration, 2016); https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-clinical-trials-live-biotherapeutic-products-chemistry-manufacturing-and-control-information

Heavey, M. K., Durmusoglu, D., Crook, N. & Anselmo, A. C. Discovery and delivery strategies for engineered live biotherapeutic products. Trends Biotechnol. 40, 354–369 (2022).

Article  CAS  PubMed  Google Scholar 

Charbonneau, M. R., Isabella, V. M., Li, N. & Kurtz, C. B. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat. Commun. 11, 1738 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, F., Luo, W., Shi, Y., Fan, Z. & Ji, G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am. J. Gastroenterol. 107, 1755 (2012).

Article  PubMed  Google Scholar 

Van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).

Article  PubMed  Google Scholar 

Bhide, A. & Datar, S. M. Fecal Microbiota Transplants—Too Simple to be Safe? Case Histories of Transformational Advance Working Paper 21-132 (Harvard Business School, 2021).

Fecal Microbiota Products (US Food and Drug Administration, 2023); https://www.fda.gov/vaccines-blood-biologics/fecal-microbiota-products

Lai, C. Y. et al. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment. Pharmacol. Ther. 49, 354–363 (2019).

Article  PubMed  Google Scholar 

Baunwall, S. M. D. et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. eClinicalMedicine 29, 100642 (2020).

Article  PubMed  Google Scholar 

Deshpande, A. et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect. Control Hosp. Epidemiol. 36, 452–460 (2015).

Article  PubMed  Google Scholar 

Finch Therapeutics Group. Finch Therapeutics announces decision to discontinue phase 3 trial of CP101 and focus on realizing the value of its intellectual property estate and other assets. GlobeNewswire https://www.globenewswire.com/news-release/2023/01/24/2594151/0/en/Finch-Therapeutics-Announces-Decision-to-Discontinue-Phase-3-Trial-of-CP101-and-Focus-on-Realizing-the-Value-of-Its-Intellectual-Property-Estate-and-Other-Assets.html (2023).

Liu, X., Li, Y., Wu, K., Shi, Y. & Chen, M. Fecal microbiota transplantation as therapy for treatment of active ulcerative colitis: a systematic review and meta-analysis. Gastroenterol. Res. Pract. 2021, 6612970 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Zhou, S., Cui, Y., Zhang, Y., Zhao, T. & Cong, J. Fecal microbiota transplantation for induction of remission in Crohn’s disease: a systematic review and meta-analysis. Int. J. Colorectal Dis. 38, 62 (2023).

Article  PubMed  Google Scholar 

Seres Therapeutics announces topline results for SER-287 phase 2b study in mild-to-moderate ulcerative colitis. Seres Therapeutics https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-announces-topline-results-ser-287-phase-2b (2021).

Alabdaljabar, M. S. et al. Restoration of the original inhabitants: a systematic review on fecal microbiota transplantation for graft-versus-host disease. Cureus 14, e23873 (2022).

PubMed  PubMed Central  Google Scholar 

MaaT pharma announces first patient dosed in phase 3 ‘ARES’ trial evaluating MaaT013 in patients with acute graft-vs-host-disease. MaaT Pharma https://www.maatpharma.com/maat-pharma-announces-first-patient-dosed-in-phase-3-ares-trial-evaluating-maat013-in-patients-with-acute-graft-vs-host-disease/ (2022).

Xu, D. et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. Am. J. Gastroenterol. 114, 1043–1050 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Zhang, Z. et al. Impact of fecal microbiota transplantation on obesity and metabolic syndrome—a systematic review. Nutrients 11, 2291 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zecheng, L. et al. Fecal microbiota transplantation in obesity metabolism: a meta analysis and systematic review. Diabetes Res. Clin. Pract. 202, 110803 (2023).

Article  PubMed  Google Scholar 

Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).

Article  CAS  PubMed  Google Scholar 

Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcella, C. et al. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment. Pharmacol. Ther. 53, 33–42 (2021).

Article  PubMed  Google Scholar 

McGovern, B. H. et al. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial. Clin. Infect. Dis. 72, 2132–2140 (2021).

Article  CAS  PubMed  Google Scholar 

Saha, S., Mara, K., Pardi, D. S. & Khanna, S. Long-term safety of fecal microbiota transplantation for recurrent Clostridioides difficile infection. Gastroenterology 160, 1961–1969.e3 (2021).

Article  PubMed  Google Scholar 

DeFilipp, Z. et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043–2050 (2019).

Article  PubMed  Google Scholar 

Fecal Microbiota for Transplantation: Safety Alert—Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms (US Food and Drug Administration, 2020); https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission

Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies (US Food and Drug Administration, 2022); https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances

Faecal Microbiota Transplant Products Regulation (Therapeutic Goods Administration, 2023); https://www.tga.gov.au/products/biologicals-blood-and-tissues-and-advanced-therapies/biologicals/faecal-microbiota-transplant-products-regulation

Faecal Microbiota Transplantation: EU-IN Horizon Scanning Report (European Medicines Agency & Heads of Medicines Agencies, 2022); https://www.pharmabiotic.org/eu-innovation-network-ema-horizon-scanning-report-fmt/